CAJ | 학술논문

目的观察瑞舒伐他汀对2型糖尿病合并高脂血症患者调脂及降低白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)及C反应蛋白(CRP)水平的作用.方法 42例2型糖尿病并高脂血症患者,口服瑞舒伐他汀10 mg/d,疗程4周,观察治疗前后血脂及IL-6、TNF-α及CRP水平.结果治疗后患者血清TC、TG、LDL-C均有明显下降[(4.3±1.8) mol/L比(6.2±2.0) mol/L；(1.5±0.8)mol/L比(2.4±1.3) mol/L；(2.3 ±0.8)mol/L比(3.2±0.8)mol/L],差异有统计学意义(均P＜0.05)；治疗后所有患者的IL-6、TNF-α 及CRP均较治疗前下降[分别为(27.2±12.6) μg/L比(60.5 ±20.3)μg/L；(0.21 ±0.15) μg/L比(0.32±0.09) μg/L；(4.91 ±0.13) mg/L比(5.87 ±0.21 )mg/L,均P＜0.05].结论瑞舒伐他汀可有效降低糖尿病高脂血症患者的血脂水平,亦可明显降低炎症因子水平,有利于改善糖尿病大血管病变.
목적 관찰서서벌타정대2형당뇨병합병고지혈증환자조지급강저백세포개소6(IL-6)、종류배사인자α(TNF-α)급C반응단백(CRP)수평적작용.방법 42례2형당뇨병병고지혈증환자,구복서서벌타정10 mg/d,료정4주,관찰치료전후혈지급IL-6、TNF-α급CRP수평.결과 치료후환자혈청TC、TG、LDL-C균유명현하강[(4.3±1.8) mol/L비(6.2±2.0) mol/L；(1.5±0.8)mol/L비(2.4±1.3) mol/L；(2.3 ±0.8)mol/L비(3.2±0.8)mol/L],차이유통계학의의(균P＜0.05)；치료후소유환자적IL-6、TNF-α 급CRP균교치료전하강[분별위(27.2±12.6) μg/L비(60.5 ±20.3)μg/L；(0.21 ±0.15) μg/L비(0.32±0.09) μg/L；(4.91 ±0.13) mg/L비(5.87 ±0.21 )mg/L,균P＜0.05].결론 서서벌타정가유효강저당뇨병고지혈증환자적혈지수평,역가명현강저염증인자수평,유리우개선당뇨병대혈관병변.
Objective To observe the effects of rosuvastatin on regulating blood lipid level and serum inflammation factor levels in diabetes patient with hyperlipidemia,including interleukin-6 (IL-6),tumor necrosis factor alpha (TNF-α) and C-creactive protein(CRP).Methods Forty-two cases of type 2 diabetes patients with hyperlipidemia were given rosuvastatin 10mg each night for 4 weeks.Levels of blood lipid,IL-6,CRP and TNF-α were detected before and after treatment.Results After treatment with rosuvastatin,the serum TC,TG,LDL-C,were significantly decreased [ (4.3 ± 1.8 ) mol/L vs (6.2 ± 2.0) mol/L; ( 1.5 ± 0.8 ) mol/L vs (2.4 ± 1.3 ) mol/L; (2.3± 0.8) mol/L vs (3.2 ± 0.8) mol/L,all P ＜ 0.05 ],and the serum levels of IL-6,TNF-α and CRP were significantly decreased[ (27.2 ± 12.6) μg/L vs (60.5 ±20.3) μg/L; (0.21 ±0.15) μg/L vs (0.32 ±0.09) μg/L;(4.91 ±0.13)mg/L vs (5.87 ±0.21 )mg/L,all P ＜0.05].Conclusion Rosuvastatin can significantly decrease the levels of blood lipid and serum Inflammation Factor in diabetes patient with hyperlipidemia.